RecruitingPhase 4NCT05285566

Pain Control for Undergoing Costal Cartilage Harvesting

A Phase IV Randomized, Single-Blind Trial of Liposomal Bupivacaine (Exparel®) for Pain Control in Costal Cartilage Harvest

Sponsor

Mayo Clinic

Enrollment

60 participants

Start Date

May 4, 2022

Study Type

INTERVENTIONAL

Conditions

Nasal Surgery

Summary

The purpose of this study is to find out whether injecting the U.S. Food and Drug Administration (FDA) approved drug EXPAREL®, a long acting (approximately 96 hours) numbing medication, will reduce pain after rib cartilage removal in comparison to the standard injection of XYLOCAINE®.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Exparel and a drug called Xylocaine for people with nasal surgery. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGExparel

106mg (8 mL) subcutaneous injection injected after costal cartilage harvest

DRUGXylocaine

8 mL of 1% lidocaine with 1:100,000 of epinephrine into costal cartilage wound site

Locations(1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05285566

Related Trials

Lateral Crural Steal With Columellar Strut Graft in Primary Open Rhinoplasty

NCT073179471 location

Performance of EEG During Emergence Agitation in Nasal Surgery.

NCT056543111 location